Yeast Hydrolysate and Postmenopausal Osteoporosis
Abstract
:1. Introduction
2. Materials and Methods
2.1. Preparation of YH
2.2. Animals and Diets
2.3. Biochemical Analyses
2.4. Microcomputed Tomography (μ-CT) Bone Analyses
2.5. Statistical Analyses
3. Results and Discussion
4. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
Abbreviations
References
- Li, X.; Ominsky, M.S.; Warmington, K.S.; Morony, S.; Gong, J.; Cao, J.; Gao, Y.; Shalhoub, V.; Tipton, B.; Haldankar, R.; et al. Sclerostin antibody treatment increases bone formation, bone mass, and bone strength in a rat model of postmenopausal osteoporosis. J. Bone Miner. Res. 2009, 24, 578–588. [Google Scholar] [CrossRef] [PubMed]
- Watts, N.B.; Harris, S.T.; Genant, H.K.; Wasnich, R.D.; Miller, P.D.; Jackson, R.D.; Licata, A.A.; Ross, P.; Woodson, G.C., 3rd; Yanover, M.J.; et al. Intermittent cyclical etidronate treatment of postmenopausal osteoporosis. N. Engl. J. Med. 1990, 323, 73–79. [Google Scholar] [CrossRef] [PubMed]
- Gruber, H.E.; Ivey, J.L.; Baylink, D.J.; Matthews, M.; Nelp, W.B.; Sisom, K.; Chesnut, C.H. Long-term calcitonin therapy in postmenopausal osteoporosis. Metab. Clin. Exp. 1984, 33, 295–303. [Google Scholar] [CrossRef]
- Kalu, D.N. The ovariectomized rat model of postmenopausal bone loss. Bone Miner. 1991, 15, 175–191. [Google Scholar] [CrossRef] [PubMed]
- Li, X.X.; Hara, I.; Matsumiya, T. Effects of osthole on postmenopausal osteoporosis using ovariectomized rats; Comparison to the effects of estradiol. Biol. Pharm. Bull. 2002, 25, 738–742. [Google Scholar] [CrossRef] [PubMed]
- Thompson, D.D.; Simmons, H.A.; Pirie, C.M.; Ke, H.Z. FDA guidelines and animal-Models for osteoporosis. Bone 1995, 17, S125–S133. [Google Scholar] [CrossRef] [PubMed]
- Lindsay, R.; Tohme, J.F. Estrogen-treatment of patients with established postmenopausal osteoporosis. Obstet. Gynecol. 1990, 76, 290–295. [Google Scholar]
- Lufkin, E.G.; Wahner, H.W.; Ofallon, W.M.; Hodgson, S.F.; Kotowicz, M.A.; Lane, A.W.; Judd, H.L.; Caplan, R.H.; Riggs, B.L. Treatment of postmenopausal osteoporosis with transdermal estrogen. Annas Intern. Med. 1992, 117, 1–9. [Google Scholar] [CrossRef]
- Nishizawa, Y.; Nakamura, T.; Ohta, H.; Kushida, K.; Gorai, I.; Shiraki, M.; Fukunaga, M.; Hosoi, T.; Miki, T.; Chaki, O.; et al. Guidelines for the use of biochemical markers of bone turnover in osteoporosis (2004). J. Bone Miner. Metab. 2005, 23, 97–104. [Google Scholar] [CrossRef]
- Delmas, P.D.; Eastell, R.; Garnero, P.; Seibel, M.J.; Stepan, J. The use of biochemical markers of bone turnover in osteoporosis. Osteoporos. Int. 2000, 11, 2–17. [Google Scholar] [CrossRef]
- Anderson, G.L.; Judd, H.L.; Kaunitz, A.M.; Barad, D.H.; Beresford, S.A.A.; Pettinger, M.; Liu, J.; McNeeley, S.G.; Lopez, A.M. Effects of estrogen plus progestin on gynecologic cancers and associated diagnostic procedures—The Women’s Health Initiative randomized trial. J. Am. Med. Assoc. 2003, 290, 1739–1748. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Banks, E.; Beral, V.; Bull, D.; Reeves, G.; Austoker, J.; English, R.; Patnick, J.; Peto, R.; Vessey, M.; Wallis, M.; et al. Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet 2003, 362, 419–427. [Google Scholar]
- Morabito, N.; Crisafulli, A.; Vergara, C.; Gaudio, A.; Lasco, A.; Frisina, N.; D’Anna, R.; Corrado, F.; Pizzoleo, M.A.; Cincotta, M.; et al. Effects of genistein and hormone-replacement therapy on bone loss in early postmenopausal women: A randomized double-blind placebo-controlled study. J. Bone Miner. Res. 2002, 17, 1904–1912. [Google Scholar] [CrossRef]
- Arjmandi, B.H.; Alekel, L.; Hollis, B.W.; Amin, D.; Stacewicz-Sapuntzakis, M.; Guo, P.; Kukreja, S.C. Dietary soybean protein prevents bone loss in an ovariectomized rat model of osteoporosis. J. Nutr. 1996, 126, 161–167. [Google Scholar] [CrossRef]
- Lee, H.S.; Jung, E.Y.; Bae, S.H.; Kwon, K.H.; Kim, J.M.; Suh, H.J. Stimulation of osteoblastic differentiation and mineralization in MC3T3-E1 cells by yeast hydrolysate. Phytother. Res. 2011, 25, 716–723. [Google Scholar] [CrossRef]
- Kim, J.M.; Kim, S.Y.; Jung, E.Y.; Bae, S.H.; Suh, H.J. Yeast hydrolysate induces longitudinal bone growth and growth hormone release in rats. Phytother. Res. 2009, 23, 731–736. [Google Scholar] [CrossRef]
- Murray, W.S. Some effects of ovariectomy during the period of declining reproductive powers in mice. J. Exp. Med. 1936, 63, 893–900. [Google Scholar] [CrossRef]
- Kelly, O.; Cashman, K.D. The effect of conjugated linoleic acid on calcium absorption and bone metabolism and composition in adult ovariectomised rats. Prostaglandins Leukot. Essent. Fat. Acids 2004, 71, 295–301. [Google Scholar] [CrossRef]
- Wronski, T.J.; Cintron, M.; Dann, L.M. Temporal relationship between bone loss and increased bone turnover in ovariectomized rats. Calcif. Tissue Int. 1988, 43, 179–183. [Google Scholar] [CrossRef]
- Dang, Z.C.; Van Bezooijen, R.L.; Karperien, M.; Papapoulos, S.E.; Lowik, C.W.G.M. Exposure of KS483 cells to estrogen enhances osteogenesis and inhibits adipogenesis. J. Bone Miner. Res. 2002, 17, 394–405. [Google Scholar] [CrossRef]
- Demers, L.M. Androgen deficiency in women; role of accurate testosterone measurements. Maturitas 2010, 67, 39–45. [Google Scholar] [CrossRef]
- Overlie, I.; Moen, M.H.; Morkrid, L.; Skjaeraasen, J.S.; Holte, A. The endocrine transition around menopause-a five years prospective study with profiles of gonadotropines, estrogens, androgens and SHBG among healthy women. Acta Obstet. Gynecol. Scand. 1999, 78, 642–647. [Google Scholar] [CrossRef] [PubMed]
- Montalcini, T.; Gorgone, G.; Gazzaruso, C.; Sesti, G.; Perticone, F.; Pujia, A. Role of endogenous androgens on carotid atherosclerosis in non-obese postmenopausal women. Nutr. Metab. Cardiovasc. Dis. 2007, 17, 705–711. [Google Scholar] [CrossRef] [PubMed]
- Frost, H.M.; Jee, W.S. On the rat model of human osteopenias and osteoporoses. Bone Miner. 1992, 18, 227–236. [Google Scholar] [CrossRef]
- Ito, M.; Nishida, A.; Koga, A.; Ikeda, S.; Shiraishi, A.; Uetani, M.; Hayashi, K.; Nakamura, T. Contribution of trabecular and cortical components to the mechanical properties of bone and their regulating parameters. Bone 2002, 31, 351–358. [Google Scholar] [CrossRef]
- Parfitt, A.M.; Mathews, C.H.E.; Villanueva, A.R.; Kleerekoper, M.; Frame, B.; Rao, D.S. Relationships between surface, volume, and thickness of Iliac trabecular bone in aging and in osteoporosis-Implications for the microanatomic and cellular mechanisms of bone loss. J. Clin. Investig. 1983, 72, 1396–1409. [Google Scholar] [CrossRef]
- Parfitt, A.M.; Drezner, M.K.; Glorieux, F.H.; Kanis, J.A.; Malluche, H.; Meunier, P.J.; Ott, S.M.; Recker, R.R. Bone Histomorphometry-Standardization of Nomenclature, Symbols, and Units. J. Bone Miner. Res. 1987, 2, 595–610. [Google Scholar] [CrossRef] [PubMed]
- Wronski, T.J.; Dann, L.M.; Scott, K.S.; Cintron, M. Long-term effects of ovariectomy and aging on the rat skeleton. Calcif. Tissue Int. 1989, 45, 360–366. [Google Scholar] [CrossRef]
- Alexander, J.M.; Bab, I.; Fish, S.; Muller, R.; Uchiyama, T.; Gronowicz, G.; Nahounou, M.; Zhao, Q.; White, D.W.; Chorev, M.; et al. Human parathyroid hormone 1-34 reverses bone loss in ovariectomized mice. J. Bone Miner. Res. 2001, 16, 1665–1673. [Google Scholar] [CrossRef]
- Liu, C.C.; Kalu, D.N. Human parathyroid hormone (1-34) prevents bone loss and augments bone formation in sexually mature ovariectomized rats. J. Bone Miner. Res. 1990, 5, 973–982. [Google Scholar] [CrossRef]
- Lark, M.W.; Stroup, G.B.; Dodds, R.A.; Kapadia, R.; Hoffman, S.J.; Hwang, S.M.; James, I.E.; Lechowska, B.; Liang, X.; Rieman, D.J.; et al. Antagonism of the osteoclast vitronectin receptor with an orally active nonpeptide inhibitor prevents cancellous bone loss in the ovariectomized rat. J. Bone Miner. Res. 2001, 16, 319–327. [Google Scholar] [CrossRef] [PubMed]
- Devareddy, L.; Khalil, D.A.; Smith, B.J.; Lucas, E.A.; Soung, D.Y.; Marlow, D.D.; Arjmandi, B.H. Soy moderately improves microstructural properties without affecting bone mass in an ovariectomized rat model of osteoporosis. Bone 2006, 38, 686–693. [Google Scholar] [CrossRef] [PubMed]
Parameters | Sham | Control | OVX | OVX | OVX | Pooled SEM |
---|---|---|---|---|---|---|
Estrogen | YH, 0.5% | YH, 1% | ||||
BV/TV, % | 44.38 b | 38.79 ab | 44.63 b | 37.89 ab | 36.16 a | 6.21 |
Tb.N, 1/mm | 10.75 c | 7.14 a | 7.40 ab | 8.62 bc | 7.96 ab | 1.91 |
Tb.Th, mm | 57.38 | 54.05 | 63.92 | 47.10 | 46.27 | 8.32 |
Tb.Sp, mm | 54.19 a | 82.32 b | 77.37 ab | 76.98 ab | 81.73 b | 10.12 |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Hong, Y.H.; Jung, E.Y. Yeast Hydrolysate and Postmenopausal Osteoporosis. J. Pers. Med. 2023, 13, 322. https://doi.org/10.3390/jpm13020322
Hong YH, Jung EY. Yeast Hydrolysate and Postmenopausal Osteoporosis. Journal of Personalized Medicine. 2023; 13(2):322. https://doi.org/10.3390/jpm13020322
Chicago/Turabian StyleHong, Yang Hee, and Eun Young Jung. 2023. "Yeast Hydrolysate and Postmenopausal Osteoporosis" Journal of Personalized Medicine 13, no. 2: 322. https://doi.org/10.3390/jpm13020322
APA StyleHong, Y. H., & Jung, E. Y. (2023). Yeast Hydrolysate and Postmenopausal Osteoporosis. Journal of Personalized Medicine, 13(2), 322. https://doi.org/10.3390/jpm13020322